[
  {
    "challenge_name": "BSL-2+ Containment Facilities Required",
    "challenge_category": "Safety & Containment",
    "short_description": "Requires specialized biosafety infrastructure for live viral vectors",
    "explanation": "Manufacturing products involving live viral vectors (gene therapies, oncolytic viruses) requires BSL-2+ facilities with negative pressure gradients, advanced waste treatment, specialized PPE, restricted access, and emergency protocols. These facilities prevent escape of viruses that retain ability to replicate or cause infection.",
    "technology_name": "Lentiviral Vector Production",
    "severity_level": "critical",
    "related_capabilities": ["BSL-2+ Containment Facilities", "Viral Vector Manufacturing", "Biosafety & Biosecurity"]
  },
  {
    "challenge_name": "High-Potency API (HPAPI) Handling",
    "challenge_category": "Safety & Containment",
    "short_description": "Extreme containment for cytotoxic and highly potent compounds",
    "explanation": "HPAPIs at OEB 3-4 levels (≤0.1 mg/m³) can cause cancer, reproductive harm, or immune damage at microscopic doses. Requires barrier isolation, negative pressure, single-use systems, specialized waste handling, comprehensive monitoring, and validated PPE. Significantly increases timelines and costs.",
    "technology_name": "Antibody-Drug Conjugation (ADC)",
    "severity_level": "critical",
    "related_capabilities": ["High-Potency API Handling", "Isolator Technology", "Specialized waste handling"]
  },
  {
    "challenge_name": "PROTAC Manufacturing Complexity",
    "challenge_category": "Advanced Synthesis",
    "short_description": "Multi-component synthesis of large targeted protein degraders",
    "explanation": "PROTACs require assembling three molecular components (target binder, linker, E3 ligase recruiter) with >1000 Da molecular weight. Involves 5-14 synthetic steps with precise linker chemistry, advanced purification for high-MW compounds, and enhanced formulation to overcome poor bioavailability due to size and complexity.",
    "technology_name": "PROTAC Synthesis Platform",
    "severity_level": "major",
    "related_capabilities": ["PROTAC Synthesis", "Advanced Click Chemistry", "Multi-Step Organic Synthesis"]
  },
  {
    "challenge_name": "Advanced Peptide Manufacturing",
    "challenge_category": "Advanced Synthesis",
    "short_description": "Complex peptide synthesis with stereochemistry control",
    "explanation": "Solid-Phase Peptide Synthesis (SPPS) requires building peptides one amino acid at a time with extreme Process Mass Intensity (~13,000). Must control stereochemistry to prevent racemization, ensure sequence fidelity, and prevent aggregation. Requires automated synthesizers, HPLC purification, and specialized analytics.",
    "technology_name": "Multi-Step Organic Synthesis",
    "severity_level": "moderate",
    "related_capabilities": ["Multi-Step Organic Synthesis", "Stereochemistry control", "Advanced analytical methods"]
  },
  {
    "challenge_name": "Bispecific Antibody Chain Pairing",
    "challenge_category": "Complex Biologics",
    "short_description": "Controlling correct pairing of different antibody chains",
    "explanation": "Bispecific antibodies require two different heavy chains and potentially different light chains. Without engineering, only ~25% may be correctly paired due to random assembly. Requires knobs-into-holes engineering, charge-based pairing, or common light chain approaches. Challenges include low yield, complex purification, and advanced analytics.",
    "technology_name": "CHO Cell Culture Platform",
    "severity_level": "major",
    "related_capabilities": ["Mammalian Cell Culture (CHO/HEK293)", "Multi-Step Chromatography Platform", "Advanced Analytical Methods"]
  },
  {
    "challenge_name": "ADC Dual-Stream Manufacturing",
    "challenge_category": "Complex Biologics",
    "short_description": "Coordinating biologics and cytotoxic drug manufacturing",
    "explanation": "ADCs require parallel manufacturing: biologics stream (antibody via cell culture) and chemical stream (cytotoxic payload with OEB4 containment), followed by conjugation with precise Drug-to-Antibody Ratio (DAR 2-4) control. Needs dual containment capabilities, specialized conjugation equipment, and advanced analytics. Regulated as both biologics and chemical drugs.",
    "technology_name": "Antibody-Drug Conjugation (ADC)",
    "severity_level": "critical",
    "related_capabilities": ["Antibody-Drug Conjugation (ADC)", "Site-Specific Conjugation", "High-Potency API Handling"]
  },
  {
    "challenge_name": "Viral Vector Production Complexity",
    "challenge_category": "Advanced Therapies",
    "short_description": "Complex viral production with stringent purity requirements",
    "explanation": "Beyond containment, viral vectors require specialized cell culture, controlled viral replication, advanced purification separating viral particles from cellular debris, replication-competent virus (RCV) testing, potency assays, and cold chain logistics. Must remove cellular DNA/proteins that could cause immune reactions while maintaining viral infectivity.",
    "technology_name": "Triple Plasmid Transfection (AAV)",
    "severity_level": "critical",
    "related_capabilities": ["Viral Vector Manufacturing", "BSL-2+ Containment Facilities", "Empty/Full Capsid Separation"]
  },
  {
    "challenge_name": "Amorphous Solid Dispersion (ASD) Manufacturing",
    "challenge_category": "Formulation Challenge",
    "short_description": "Complex spray drying for poorly soluble compounds",
    "explanation": "Many BCS Class IV drugs require ASD to improve bioavailability. Organic spray drying demands precise control of temperature, airflow, and solvent evaporation. Challenges include polymer selection, scale-up consistency, maintaining amorphous state during storage, and preventing conversion to crystalline forms. Requires solvent recovery and specialized analytical methods.",
    "technology_name": "Spray Drying",
    "severity_level": "moderate",
    "related_capabilities": ["Amorphous Solid Dispersion (ASD) Technology", "Spray Drying Technology", "Poorly Soluble Compound Formulation"]
  },
  {
    "challenge_name": "Cold Chain Logistics",
    "challenge_category": "Distribution Challenge",
    "short_description": "Temperature-controlled supply chain from manufacturing to patient",
    "explanation": "Temperature-sensitive biologics and complex molecules lose potency or become dangerous outside specified ranges. Requires validated cold storage, specialized insulated packaging, refrigerated transportation, real-time monitoring, and contingency planning. Costs 2-5x more than ambient distribution with global infrastructure challenges.",
    "technology_name": "Cold Chain Monitoring",
    "severity_level": "critical",
    "related_capabilities": ["Cold Chain Management", "Cryogenic Storage & Handling"]
  },
  {
    "challenge_name": "High-Selectivity Synthesis Requirements",
    "challenge_category": "Purification Challenge",
    "short_description": "Achieving >300-fold enzyme selectivity",
    "explanation": "Creating molecules with >300-fold selectivity for target enzyme over related enzymes requires stereochemical precision and minimal impurities. Even trace amounts of wrong isomers or related compounds compromise selectivity. Demands rigorous purification, multi-enzyme selectivity testing, process validation, and stringent raw material control.",
    "technology_name": "Multi-Step Organic Synthesis",
    "severity_level": "major",
    "related_capabilities": ["Asymmetric Synthesis", "Ultra-High Purity Purification", "Advanced Analytical Methods"]
  },
  {
    "challenge_name": "Covalent Inhibitor Stability Control",
    "challenge_category": "Synthesis Challenge",
    "short_description": "Balancing stability and therapeutic reactivity",
    "explanation": "Covalent inhibitors must be stable during manufacturing/storage but reactive enough for therapeutic effect. Walking this tightrope requires controlled reactivity, preventing premature reactions with equipment/containers, preserving target selectivity, and extensive stability-reactivity testing. Needs inert processing, specialized storage, and continuous monitoring.",
    "technology_name": "Cryogenic Reaction Technology",
    "severity_level": "major",
    "related_capabilities": ["Multi-Step Organic Synthesis", "Transition Metal Catalysis", "Process validation"]
  },
  {
    "challenge_name": "Complex Biologics Manufacturing",
    "challenge_category": "Complex Biologics",
    "short_description": "Specialized production of fusion proteins and receptor modulators",
    "explanation": "Beyond standard mAbs, complex biologics like fusion proteins and receptor modulators have unique structural requirements affecting production, purification, and characterization. Require specialized expression systems, advanced purification preserving complex structures, structure-function analysis, and bioactivity testing. Extensive process development and novel analytical methods needed.",
    "technology_name": "HEK293 Cell Culture System",
    "severity_level": "moderate",
    "related_capabilities": ["Mammalian Cell Culture (CHO/HEK293)", "Multi-Step Chromatography Platform", "Advanced Analytical Methods"]
  },
  {
    "challenge_name": "High Titer Production (>5g/L)",
    "challenge_category": "Process Intensification",
    "short_description": "Achieving antibody titers >10 g/L",
    "explanation": "Process intensification to achieve >10 g/L antibody titers requires optimized media formulation, advanced feeding strategies, extended culture durations (14+ days), cell line engineering for high productivity, and large-scale bioreactor operation (2,000-20,000L). Benefits include reduced manufacturing footprint and cost per dose, but increases complexity of upstream processing.",
    "technology_name": "Perfusion Cell Culture",
    "severity_level": "moderate",
    "related_capabilities": ["Fed-Batch Culture Optimization", "Perfusion Culture Technology", "Cell Line Development & Engineering"]
  },
  {
    "challenge_name": "Viral Safety Testing",
    "challenge_category": "Manufacturing",
    "technology_name": "Nanofiltration (20nm)",
    "severity_level": "moderate",
    "related_capabilities": []
  },
  {
    "challenge_name": "Downstream Purification",
    "challenge_category": "Manufacturing",
    "technology_name": "Ion Exchange Chromatography (IEX)",
    "severity_level": "moderate",
    "related_capabilities": []
  },
  {
    "challenge_name": "PROTAC Manufacturing",
    "challenge_category": "Manufacturing",
    "technology_name": "PROTAC Synthesis Platform",
    "severity_level": "moderate",
    "related_capabilities": []
  },
  {
    "challenge_name": "Complex Synthesis",
    "challenge_category": "Manufacturing",
    "technology_name": "PROTAC Synthesis Platform",
    "severity_level": "moderate",
    "related_capabilities": []
  },
  {
    "challenge_name": "Advanced Formulation",
    "challenge_category": "Manufacturing",
    "technology_name": "Spray Drying",
    "severity_level": "moderate",
    "related_capabilities": []
  },
  {
    "challenge_name": "Specialized Solid-Phase Synthesis",
    "challenge_category": "Manufacturing",
    "technology_name": "Multi-Step Organic Synthesis",
    "severity_level": "moderate",
    "related_capabilities": []
  },
  {
    "challenge_name": "Complex Purification",
    "challenge_category": "Manufacturing",
    "technology_name": "High-Performance Liquid Chromatography (HPLC)",
    "severity_level": "moderate",
    "related_capabilities": []
  },
  {
    "challenge_name": "Delivery System Integration",
    "challenge_category": "Manufacturing",
    "technology_name": "Lipid Nanoparticle (LNP) Formulation",
    "severity_level": "moderate",
    "related_capabilities": []
  },
  {
    "challenge_name": "Stability Management",
    "challenge_category": "Manufacturing",
    "technology_name": "Lyophilization (Freeze-Drying)",
    "severity_level": "moderate",
    "related_capabilities": []
  },
  {
    "challenge_name": "Device & Combination Product Manufacturing",
    "challenge_category": "Manufacturing",
    "technology_name": "Auto-Injector Integration",
    "severity_level": "moderate",
    "related_capabilities": []
  },
  {
    "challenge_name": "Advanced Purification",
    "challenge_category": "Manufacturing",
    "technology_name": "Mixed-Mode Chromatography",
    "severity_level": "moderate",
    "related_capabilities": []
  },
  {
    "challenge_name": "Personalized Manufacturing",
    "challenge_category": "Manufacturing",
    "technology_name": "Ex-Vivo T-Cell Expansion",
    "severity_level": "moderate",
    "related_capabilities": []
  },
  {
    "challenge_name": "Autologous Cell Processing",
    "challenge_category": "Manufacturing",
    "technology_name": "Ex-Vivo T-Cell Expansion",
    "severity_level": "moderate",
    "related_capabilities": []
  },
  {
    "challenge_name": "Viral Transduction",
    "challenge_category": "Manufacturing",
    "technology_name": "Lentiviral Vector Production",
    "severity_level": "moderate",
    "related_capabilities": []
  },
  {
    "challenge_name": "Cryopreservation",
    "challenge_category": "Manufacturing",
    "technology_name": "Controlled-Rate Freezing",
    "severity_level": "moderate",
    "related_capabilities": []
  },
  {
    "challenge_name": "Patient-Specific Logistics",
    "challenge_category": "Manufacturing",
    "technology_name": "Cold Chain Monitoring",
    "severity_level": "moderate",
    "related_capabilities": []
  }
]